Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations

Leukemia Research

Volumn 33, Issue 6, 2009, Pages 843-846

  Fink, Stephanie R ^a   Belongie, Kimberly J ^a   Paternoster, Sarah F ^a   Smoley, Stephanie A ^a   Pardanani, Animesh D ^a   Tefferi, Ayalew ^a   Van Dyke, Daniel L ^a   Ketterling, Rhett P ^a  

^a MAYO CLINIC   (United States)

Author keywords

CHIC2; FIP1L1 PDGFRA fusion; FISH; Myeloproliferative neoplasm

Indexed keywords

DNA BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN CHIC2; PROTEIN FIP1L1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; VALIDATION STUDY;

DNA-BINDING PROTEINS; GENE DELETION; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 63349092131     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.11.016     Document Type: Article

References (8)

1. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
2. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
3. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
4. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
5. Pardanani A., and Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104 (2004) 1931-1939
6. Brockman S.R., Paternoster S.F., Ketterling R.P., and Dewald G.W. New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 145 (2003) 144-151
7. Gotlib J., Cools J., Malone III J.M., Schrier S.L., Gilliland D.G., and Coutre S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891
8. Pardanani A., Ketterling R.P., Li C.Y., Patnaik M.M., Wolanskyj A.P., Elliott M.A., et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30 (2006) 965-970